BRAF antibody

Catalog No. ABIN968991

Product Details anti-BRAF Antibody

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reactivity: Human, Mouse

Host: Mouse

Clonality: Monoclonal

Conjugate: This BRAF antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunocytochemistry (ICC)

Purification: purified

Immunogen: Purified recombinant fragment of human BRAF expressed in E. coli.

Clone: 1H12

Isotype: IgG1

Application Details

Application Notes: ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000, ICC: 1:200 - 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C/-20 °C

Storage Comment: 4°C, -20°C for long term storage

References for anti-BRAF antibody (ABIN968991)

Di Nicolantonio, Martini, Molinari, Sartore-Bianchi, Arena, Saletti, De Dosso, Mazzucchelli, Frattini, Siena, Bardelli: "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, Issue 35, pp. 5705-12, (2008) (PubMed).

Riesco-Eizaguirre, Gutiérrez-Martínez, García-Cabezas, Nistal, Santisteban: "The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane." in: Endocrine-related cancer, Vol. 13, Issue 1, pp. 257-69, (2006) (PubMed).

Target Details for BRAF

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Alternative Name: BRAF (BRAF Products)

Synonyms: B-RAF1 antibody, BRAF1 antibody, NS7 antibody, RAFB1 antibody, C-RMIL antibody, RMIL antibody, B-Raf antibody, braf1 antibody, rafb1 antibody, b-raf1 antibody, sierrabraf antibody, BRAF antibody, 9930012E13Rik antibody, AA120551 antibody, AA387315 antibody, AA473386 antibody, B-raf antibody, Braf-2 antibody, Braf2 antibody, C230098H17 antibody, C87398 antibody, D6Ertd631e antibody, braf antibody, fc48g01 antibody, wu:fc48g01 antibody, B-Raf proto-oncogene, serine/threonine kinase antibody, B-Raf proto-oncogene, serine/threonine kinase S homeolog antibody, Braf transforming gene antibody, si:dkey-222f8.3 antibody, BRAF antibody, Braf antibody, braf.S antibody, braf antibody, si:dkey-222f8.3 antibody

Background:

Description: BRAF: v-raf murine sarcoma viral oncogene homolog B1, also known as BRAF1, RAFB1, B-RAF1, FLJ95109. Entrez Protein NP_004324. It is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439). B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK), it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers. The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi, primary cutaneous melanomas and colorectal cancers.

Aliases: BRAF1, RAFB1, B-RAF1, FLJ95109

Molecular Weight: 87 kDa

Gene ID: 673

HGNC: 673

Pathways: MAPK Signaling, RTK Signaling, Neurotrophin Signaling Pathway, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagy